Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLORAL long-term etavopivat extension study in sickle cell disease or thalassaemia
PACTR202408476236496Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label trial of etavopivat in sickle cell disease (SCD) and Thalassaemia (2 arms), sponsored by Novo Nordisk. Primary endpoints: Number of treatment-emergent adverse events and Number of adverse reactions. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)Thalassaemia
Beyond the preview
Go deeper on PACTR202408476236496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202408476236496.